Healthcare
Live Price
Offline$4.73
-0.42% today
1Y Change
+38.33%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Tilray Brands, Inc. (TLRY) is a Healthcare stock with a market cap of $740.00M and listed on NASDAQ. The stock last traded around $4.73 and up 38.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of -651.1%, a dividend yield of 0.0%. What stands out right now is revenue +4.8%, EPS -651.1%, free cash flow -113.5% with operating margin -172.3% and ROIC -100.9%. Valuation is more restrained than many high-expectation growth names at price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines TLRY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLRY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLRY Max Drawdown
-76.48%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLRY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$619.7M
-21.8% YoY
FY Net Income
-$443.7M
+26.2% YoY
Free Cash Flow
-$100.9M
+62.1% YoY
Revenue Growth
+4.8%
EPS Growth
-651.1%
Gross Margin
27.7%
Net Margin
-156.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.1B | 1.1B | 845M | 792M | 620M |
| Gross Profit | 330M | 304M | 198M | 147M | 149M |
| Operating Income | -3.1B | -238M | -1.8B | -769M | -160M |
| EBITDA | -2.9B | -99M | -1.7B | -311M | -297M |
| Net Income | -3.0B | -334M | -2.0B | -601M | -444M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 304M | 311M | 278M | 524M | 488M |
| Total Assets | 2.9B | 5.9B | 5.9B | 6.9B | 6.0B |
| Total Liabilities | 860M | 1.2B | 1.4B | 1.3B | 1.6B |
| Shareholder Equity | 2.1B | 4.7B | 4.5B | 5.5B | 4.5B |
| Total Debt | 451M | 528M | 795M | 786M | 939M |
| Net Debt | 147M | 217M | 517M | 262M | 450M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
+75.8% YoY
Capital Expenditures
47M
-9.3% YoY
Free Cash Flow
101M
+62.1% YoY
Key ratios
Gross Margin
27.7%
Operating Margin
-172.3%
Net Margin
-156.2%
ROE
-92.8%
Debt / Equity
0.20x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.